<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582047</url>
  </required_header>
  <id_info>
    <org_study_id>INFLUENZAPNEUMO</org_study_id>
    <nct_id>NCT02582047</nct_id>
  </id_info>
  <brief_title>Influenza Vaccine and Pneumococcal Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of an Influenza Vaccine Administered Concomitantly With a 13-Valent Pneumococcal Conjugate Vaccine or 23-Valent Polysaccharide Pneumococcal Vaccine in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have demonstrated the immunogenicity and safety of the co-administration of
      the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal
      vaccine (PPV) or pneumococcal conjugate vaccine (PCV). However, there is no direct comparison
      study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or
      PPV23 in the elderly. This study is intended to compare the immunogenicity and safety of
      concomitant administration in the elderly subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the influenza vaccination period, 224 healthy elderly volunteers randomly received
      IIV3 given concomitantly with either PCV13 (PCV13+IIV3) or PPV23 (PPV23+IIV3) in a 1:1 ratio.
      Serum hemagglutination-inhibiting (HI) antibodies for IIV3 were measured at the time of
      vaccination and 1 month after vaccination. Adverse events were recorded prospectively in a
      clinical diary during a 7-day period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rates (A/H1N1, A/H3N2, and B)</measure>
    <time_frame>Change from baseline titer at 4 weeks</time_frame>
    <description>Seroconversion: a post-vaccination titer ≥1:40 in subjects with a pre-vaccination titer of &lt;1:10 or a ≥4-fold titer increase in subjects with a pre-vaccination titer of ≥1:10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rates (A/H1N1, A/H3N2, and B)</measure>
    <time_frame>Change from baseline titer at 4 weeks</time_frame>
    <description>Seroprotection rate: percentage of subjects with a post-vaccination titer ≥1:40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT folds (A/H1N1, A/H3N2, and B)</measure>
    <time_frame>Change from baseline titer at 4 weeks</time_frame>
    <description>GMT-fold change: GMT ratio of the post-vaccination titer to pre-vaccination titer</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency and duration of local and systemic adverse events</measure>
    <time_frame>Monitor using a clinical diary for seven days after vaccination</time_frame>
    <description>the Food and Drug Administration Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Influenza, Human</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Influenza vaccination with PPV23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concomitant vaccination with trivalent inactivated influenza vaccine and 23-valent polysaccharide pneumococcal vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccination with PCV13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concomitant vaccination with trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccination with PPV23</intervention_name>
    <description>GCflu and Pneumovax-23</description>
    <arm_group_label>Influenza vaccination with PPV23</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccination with PCV13</intervention_name>
    <description>GCflu and Prevenar-13</description>
    <arm_group_label>Influenza vaccination with PCV13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged ≥65 years who signed the informed consent

        Exclusion Criteria:

          -  Previous pneumococcal vaccine recipients

          -  Egg allergy

          -  History of serious adverse event after vaccination

          -  Any acute disease or infection

          -  History of neurological symptoms or signs

          -  Impairment of immune function or immunosuppressant use

          -  Bleeding diathesis

          -  Fever (defined as axillary temperature ³38.0°C) within 3 days

          -  History of Streptococcal pneumoniae infection within the previous 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Jin Cheong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Kyoungido</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Gangnam Sacred Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Hee Jin Cheong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>influenza vaccine</keyword>
  <keyword>pneumococcal vaccine</keyword>
  <keyword>simultaneous vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

